Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Furosemide

FDA-approved product (tablet, oral), marketed as Furoscix, Furoscix Readyflow (Autoinjector), Furosemide and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Furosemide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Pulmonary edema
  • Syndromic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Loop Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Furosemide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Furosemide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Furosemide Stress Test to Predict Successful Liberation From RRT

    NCT05612490 · start 2023-01-17

    Registered record
    Registry ID
    NCT05612490
    Conditions
    Acute Kidney Injury
    Interventions
    Furosemide stress test
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-01-17
    Completion
    2025-07-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury
    InterventionFurosemide stress test
    PhaseNot recorded
    Registry statusCompleted

  • Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

    NCT05174312 · start 2022-07-11

    Registered record
    Registry ID
    NCT05174312
    Conditions
    Acute Decompensated Heart Failure
    Interventions
    Reprieve Decongestion Management System; Diuretic
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-07-11
    Completion
    2025-01-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Decompensated Heart Failure
    InterventionReprieve Decongestion Management System; Diuretic
    PhaseNot applicable
    Registry statusCompleted

  • 18F-DOPA II - PET Imaging Optimization

    NCT04706910 · start 2021-01-20

    Registered record
    Registry ID
    NCT04706910
    Conditions
    Congenital Hyperinsulinism; Neuroblastoma; Parkinson Disease; Lewy Body Disease; Neuroendocrine Tumors; Brain Tumor
    Interventions
    18F-DOPA; Furosemide Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-01-20
    Completion
    2027-12
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Hyperinsulinism; Neuroblastoma; Parkinson Disease; Lewy Body Disease +2 more
    Intervention18F-DOPA; Furosemide Injection
    PhasePhase 3
    Registry statusRecruiting

  • An Open-label, Non Significant Risk, Adhesive Wear Validation Study for the On Body Drug Delivery Device Component of the SQIN-01 Furosemide Infusor (Infusor Device)

    NCT04836572 · start 2021-01-20

    Registered record
    Registry ID
    NCT04836572
    Conditions
    Healthy Volunteer Study
    Interventions
    3M 1529 Adhesive Tape
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-20
    Completion
    2021-03-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer Study
    Intervention3M 1529 Adhesive Tape
    PhaseNot applicable
    Registry statusCompleted

  • Amiloride in Nephrotic Syndrome

    NCT05079789 · start 2020-06-08

    Registered record
    Registry ID
    NCT05079789
    Conditions
    Nephrotic Syndrome; Edema; Sodium Retention
    Interventions
    Amiloride; Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-06-08
    Completion
    2022-11-20
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNephrotic Syndrome; Edema; Sodium Retention
    InterventionAmiloride; Furosemide
    PhasePhase 3
    Registry statusTerminated

  • A Study Comparing Restrictive and Liberal Fluid Therapy During Pancreatecoduodenectomy Surgery

    NCT07072897 · start 2020-05-01

    Registered record
    Registry ID
    NCT07072897
    Conditions
    Pancreatic Cancer, Resected; Whipple Procedure
    Interventions
    Fluid bolus administration; Frusemide was given when required
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-05-01
    Completion
    2021-08-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer, Resected; Whipple Procedure
    InterventionFluid bolus administration; Frusemide was given when required
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Use of Diuretics in Maintenance Hemodialysis Patients Undergoing Bioimpedance-guided Fluid Management

    NCT04182854 · start 2019-10-28

    Registered record
    Registry ID
    NCT04182854
    Conditions
    Diuretic Abuse
    Interventions
    Furosemid hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-10-28
    Completion
    2021-07-01
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiuretic Abuse
    InterventionFurosemid hydrochlorothiazide
    PhaseNot applicable
    Registry statusUnknown

  • FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU

    NCT03731117 · start 2019-07-15

    Registered record
    Registry ID
    NCT03731117
    Conditions
    Acute Kidney Injury
    Interventions
    Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-07-15
    Completion
    2020-12-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury
    InterventionFurosemide
    PhasePhase 4
    Registry statusTerminated

  • Furosemide-induced Diuresis With Matched Dehydration Compared to Standard Diuretic Therapy in Patients With Acute Heart Failure and Overt Fluid Overload

    NCT05807152 · start 2019-02-19

    Registered record
    Registry ID
    NCT05807152
    Conditions
    Acute Decompensated Heart Failure
    Interventions
    RenalGuard device
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-02-19
    Completion
    2024-12-31
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Decompensated Heart Failure
    InterventionRenalGuard device
    PhaseNot applicable
    Registry statusUnknown

  • Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

    NCT04481789 · start 2018-10-17

    Registered record
    Registry ID
    NCT04481789
    Conditions
    Healthy Adult Subjects
    Interventions
    MT-1186; Rosuvastatin; Sildenafil; Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-10-17
    Completion
    2019-01-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Subjects
    InterventionMT-1186; Rosuvastatin; Sildenafil; Furosemide
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach

    NCT03772262 · start 2018-04-05

    Registered record
    Registry ID
    NCT03772262
    Conditions
    Interaction Drug Food
    Interventions
    goldenseal; Metformin; Furosemide; Midazolam oral solution; Rosuvastatin Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-04-05
    Completion
    2019-03-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInteraction Drug Food
    Interventiongoldenseal; Metformin; Furosemide; Midazolam oral solution +1 more
    PhaseEarly phase 1
    Registry statusCompleted

  • Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy

    NCT02960412 · start 2017-05-01

    Registered record
    Registry ID
    NCT02960412
    Conditions
    Cystoscopy
    Interventions
    furosemide; Normal Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2018-06-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystoscopy
    Interventionfurosemide; Normal Saline
    PhasePhase 4
    Registry statusCompleted

  • Product Design Clinical Performance Study of sc2Wear Furosemide Combination Product

    NCT02804282 · start 2016-07

    Registered record
    Registry ID
    NCT02804282
    Conditions
    Heart Failure
    Interventions
    sc2Wear Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-07
    Completion
    2016-11
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    Interventionsc2Wear Furosemide
    PhasePhase 3
    Registry statusCompleted